Drugs / Bivalent Oral Polio Vaccine (bOPV)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04232943 | Jan 2020 → Feb 2021 | poliomyelitis | PATH | Completed | No outcome recorded |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT01831050 | May 2013 → Apr 2014 | poliomyelitis | Fidec Corporation | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT06748612 Comparator | Jan 2025 → Dec 2027 expected | poliomyelitis | International Centre for Diarrhoeal Disease Research, Bangladesh | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bivalent oral polio vaccine (bOPV) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06748612 ↗ |
| Modality | Vaccine | “bivalent OPV vaccine contains types 1 and 3 polioviruses” NCT01831050 ↗ |
| Route | Oral | “Bivalent oral polio vaccine (bOPV)” NCT06748612 ↗ |